跳至主要内容
临床试验/EUCTR2004-000152-16-ES
EUCTR2004-000152-16-ES进行中(未招募)1 期

An international open-label extension trial to determine safety and efficacy of longterm oral SPM 927 in patients with partial seizuresEnsayo de extensión, internacional y abierto, para determinar la seguridad y la eficacia de la administración oral a largo plazo de SPM 927 en pacientes con crisis parciales.

SCHWARZ BIOSCIENCES GmbH0 个研究点目标入组 376 人开始时间: 2005年5月30日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
376

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Subjects must fulfill the following inclusion criteria:
  • 1. Subject is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent.
  • 2. Subject has completed the Maintenance and Transition Phases of the clinical trial, SP755, for the treatment of partial seizures.
  • 3. Subject is expected to benefit from participation, in the opinion of the investigator.
  • 4. Subject is willing and able to comply with all trial requirements.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Subjects are not permitted to enroll in the trial if any of the following criteria are met:
  • 1. Subject is receiving any investigational drugs or using any experimental devices in addition to SPM 927.
  • 2. Subject meets the withdrawal criteria for the previous trial (SP755) or is experiencing an ongoing serious adverse event.

研究者

发起方
SCHWARZ BIOSCIENCES GmbH

相似试验